AMR Lab · DeCure for X
DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for mycosis fungoides — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for mycosis fungoides is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
dihydrofolate reductase (DHFR) — DHFR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 4M6J · 1.201 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
A 56-year-old woman with mycosis fungoides refractory to standard therapies entered a phase 2 trial of alemtuzumab. She developed pure red-cell aplasia due to parvovirus B19 infection. The abstract does not report any response or survival data for the mycosis fungoides itself.
Seven patients with stage IV mycosis fungoides received cyclophosphamide, vincristine, methotrexate, and prednisone (COMP). The complete response rate was 57%, and the overall response was 100% in patients with limited prior steroid or chemotherapy. Complete responses lasted from 4+ to 20 months, with a median of 11 months. Overall survival ranged from 2 to 40+ months, with a median of 12+ months. One treatment-related death occurred.
Four consecutive patients received cyclophosphamide, vincristine, and prednisone (COP). One had a complete remission lasting 15 months. Another had 50% regression of tumors with healing of ulcerated surfaces. A third showed complete clearing of scaling and redness of the skin. The fourth patient’s lesions progressed.
No controlled trial data exist for any of these regimens in mycosis fungoides. The COMP and COP studies are small, decades old, and lack standardised staging or randomisation. Alemtuzumab’s effect on the disease itself is not reported. What is missing is a prospective, randomised trial with modern staging, adequate sample size, and funding to test any of these drugs against current standard care.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractA 56-year-old woman was diagnosed with mycosis fungoides 10 years earlier. Her cutaneous manifestations were widespread patches, plaques, and ultimately tumor nodules. Her disease was refractory to standard therapies, and she had no histocompatible sibling. She subsequently entered a phase 2
https://doi.org/10.1182/blood-2002-09-2923AbstractJournal Article Mycosis Fungoides: Diagnosis and Pathogenesis Get access Maurice Barcos, M.D., PH.D. Maurice Barcos, M.D., PH.D. Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York. Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 99, Issue 4, 1 April 1993, Pages 452–458, https://doi.org/10.1093/ajcp/99.4.452 Published: 01 April 1993 Article history Received: 26 October 1992 Accepted: 30 October 1992 Published: 01 April 1993
https://doi.org/10.1093/ajcp/99.4.452AbstractSeven patients with stage IV mycosis fungoides [TNM classification] have been treated with combination chemotherapy consisting of cyclophosphamide, vincristine, methotrexate, and prednisone [COMP]. A complete response rate of 57% was produced with an overall response of 100% in patients having limited prior steroid and/or chemotherapy. Complete responses range from 4+ to 20 months [median, 11 months]. Overall survival ranges from 2 to 40+ months [median, 12+ months]. The protocol was well tolerated except for one treatment-related death. Combination chemotherapy can produce effective remissions in patients with advanced mycosis fungoides. TNM classification should be considered in staging patients with mycosis fungoides for comparison of different treatment regimens.
https://doi.org/10.1097/00000421-198410000-00012AbstractFour consecutive patients with mycosis fungoides received cyclic chemotherapy using cyclophosphamide, vincristine, and prednisone (COP). In one case, there was complete remission of disease for 15 months. In another, there was 50% regression of tumors with healing of the ulcerated surfaces. The third patient showed complete clearing of scaling and redness of the skin. In the fourth patient, the lesions progressed.
https://doi.org/10.1097/00007611-197607000-00038Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
